Nanjing Medical University
南京医科大学
Hospitals that carry this university's name, added together, plus papers and trials that name only the university.
Research activity, not treatment quality. Not medical advice. How this works
Nasopharyngeal carcinoma
鼻咽癌Led 33 of 2,375 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (23.4%).
- Open trials led
- 1
- Research papers it led
- 33
- Trials it led
- 5
- Share of China's trials
- 0.8%
- Share of the world's papers
- 1.0%
Over half of these papers are lab or animal studies.
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- The Impact of Whole-Course Immunonutrition Management on Patients With Stage III and IV Nasopharyngeal Carcinoma Undergoing Concurrent Chemoradiotherapy: A Randomized Controlled Trial.
- Radiomic analysis based on machine learning of multi-sequences MR to assess early treatment response in locally advanced nasopharyngeal carcinoma.
- Delineation Errors Caused by Replication and Expansion Operations in Monaco.
- Tumor habitat-based MRI features assessing early response in locally advanced nasopharyngeal carcinoma.
- Improving the performance of deep learning models in predicting and classifying gamma passing rates with discriminative features and a class balancing technique: a retrospective cohort study.
Trials on ClinicalTrials.gov6
- Prospective Study for Molecular Biomarkers and Spatial Transcriptomics of Nasopharyngeal Carcinoma
- QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.
- Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response
- Retrospective Study on the Prediction of Radiation-induced Brain Injury in Patients With Nasopharyngeal Carcinoma
- A New EBV Related Technologies of T Cells in Treating Malignant Tumors and Clinical Application
- NPC Staged N2-3M0:Adjuvant Chemotherapy or Just Observation After Concurrent Chemoradiation
Oesophageal squamous cell carcinoma
食管鳞状细胞癌Led 108 of 2,923 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (6.9%).
- Open trials led
- 10
- Research papers it led
- 108
- Trials it led
- 17
- Share of China's trials
- 3.0%
- Share of the world's papers
- 2.5%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Pembrolizumab versus chemotherapy for patients with esophageal squamous cell carcinoma enrolled in the randomized KEYNOTE-181 trial in Asia.
- Short-course neoadjuvant radiotherapy combined with chemotherapy and toripalimab for locally advanced esophageal squamous cell carcinoma (SCALE-1): a single-arm phase Ib clinical trial.
- Neoadjuvant sintilimab and chemotherapy in patients with potentially resectable esophageal squamous cell carcinoma (KEEP-G 03): an open-label, single-arm, phase 2 trial.
- Polymeric micellar paclitaxel, cisplatin, and tislelizumab as first-line therapy for advanced unresectable esophageal squamous cell carcinoma: A phase II study with resistance profiling in poor responders.
- The predictive role of PNI and NRS2002 for postoperative pulmonary complications in ESCC patients undergoing neoadjuvant chemoimmunotherapy followed by McKeown esophagectomy: a retrospective cohort study.
Trials on ClinicalTrials.gov6
- Based on ctDNA-MRD Guided Adjuvant Treatment Escalation After Definitive Chemoradiotherapy for Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: a Study on Safety and Efficacy
- Exploratory Clinical Trial of Oral Paclitaxel Plus Radiotherapy in Patients With Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma
- A Clinical Study on the Efficacy and Safety of Paclitaxel Polymeric Micelles and Cisplatin Combined With Cadonilimab as a Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma
- Nimotuzumab Plus Definite Chemoradiotherapy(dCRT) in Elderly Patients With Esophageal Squamous Cell Carcinoma
- Trilaciclib for the Prevention of Chemoradiotherapy-Induced Myelosuppression in Esophageal Squamous Cell Carcinoma
- Sintilimab With Chemotherapy Plus PEG-rhG-GSF for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma
Hepatocellular carcinoma
肝细胞癌Led 250 of 14,765 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (5.5%).
- Open trials led
- 6
- Research papers it led
- 250
- Trials it led
- 11
- Share of China's trials
- 0.8%
- Share of the world's papers
- 0.9%
Over half of these papers are lab or animal studies.
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial.
- FOLFOX-HAIC for Unresectable Large Hepatocellular Carcinoma: The Effectiveness Has Yet to be Determined.
- Hypoxia-induced RCOR2 promotes macrophage M2 polarization and CD8+ T-cell exhaustion by enhancing LIF transcription in hepatocellular carcinoma.
- eIF3f promotes tumour malignancy by remodelling fatty acid biosynthesis in hepatocellular carcinoma.
- Endothelial DGKG promotes tumor angiogenesis and immune evasion in hepatocellular carcinoma.
Trials on ClinicalTrials.gov6
- Clinical Study on the Effectiveness and Safety of Lenvatinib As Adjuvant Treatment for Patients with High-risk Recurrence of Hepatocellular Carcinoma After Surgery
- A Single-Arm, Multicenter, Exploratory Clinical Study of TACE Combined With Iparomlimab and Tuvonralimab Injection (QL1706) and Lenvatinib for Perioperative Treatment of Resectable Hepatocellular Carcinoma
- Recurrent Liver Cancer: Reconceptualization and Reevaluation
- Immunotherapy for Hepatocellular Carcinoma
- Camrelizumab Combined With Apatinib Mesylate and TACE in the Perioperative Treatment of Hepatocellular Carcinoma
- Goal-directed LCVP Based on HP in Laparoscopic Hepatectomy
Stomach cancer
胃癌Led 378 of 9,782 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (3.9%).
- Open trials led
- 25
- Research papers it led
- 378
- Trials it led
- 41
- Share of China's trials
- 2.8%
- Share of the world's papers
- 1.8%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Electroacupuncture Reduces Duration of Postoperative Ileus After Laparoscopic Gastrectomy for Gastric Cancer: A Multicenter Randomized Trial.
- Yiqi Huayu Jiedu decoction enhances pathological response in neoadjuvant chemotherapy-treated gastric cancer patients: A prospective, randomized controlled trial.
- A prospective randomized trial comparing the pocket-creation method and conventional method of endoscopic submucosal dissection in early gastric cancers and precancerous lesions.
- Radiomics signature for predicting postoperative disease-free survival of patients with gastric cancer: development and validation of a predictive nomogram.
- Machine learning analysis for the noninvasive prediction of lymphovascular invasion in gastric cancer using PET/CT and enhanced CT-based radiomics and clinical variables.
Trials on ClinicalTrials.gov6
- QL1706-SOX vs SOX Alone as Neoadjuvant Therapy for Resectable Diffuse-Type Gastric Cancer
- 68Ga-labeled Cholecystokinin Receptor (CCK2R) Targeted Molecular Probes in Early Tumor Diagnosis
- Robotic vs Laparoscopic Gastrectomy for cT4a Gastric Cancer
- Disitamab Vedotin Combined With SOX Regimen Versus SOX Alone as Adjuvant Therapy for HER2-Moderate/High Expressing Stage Ⅲ Gastric Cancer: A Prospective, Multicenter, Randomized, Phase Ⅱ Clinical Trial
- Lymph Node Dissection After Neoadjuvant Therapy for Gastric and EGJ Adenocarcinoma
- Megestrol Acetate Oral Suspension for Cachexia in Patients With cStage III Gastric/Gastroesophageal Junction Adenocarcinoma Receiving Neoadjuvant Therapy With Serplulimab Combined With SOX
Hepatoblastoma
肝母细胞瘤Led 3 of 154 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (13.6%).
- Open trials led
- 0
- Research papers it led
- 3
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.7%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led3
- Effectiveness of indocyanine green fluorescence imaging in resection of hepatoblastoma.
- Nur77 inhibition of β-catenin expression mediates Hepatoblastoma progression and enhances cisplatin's therapeutic effect.
- Long non-coding RNA Linc00205 promotes hepatoblastoma progression through regulating microRNA-154-3p/Rho-associated coiled-coil Kinase 1 axis via mitogen-activated protein kinase signaling.
Retinoblastoma
视网膜母细胞瘤Led 5 of 301 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (12.0%).
- Open trials led
- 0
- Research papers it led
- 5
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.4%
Over half of these papers are lab or animal studies.
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Long Non-coding RNA FEZF1-AS1 Promotes Growth and Reduces Apoptosis Through Regulation of miR-363-3p/PAX6 Axis in Retinoblastoma.
- MicroRNA-708 suppresses the proliferation, migration, and invasion of human retinoblastoma cells by targeting RAP2B, a member of the RAS oncogene family.
- UBE2T is a prognostic biomarker and correlated with Th2 cell infiltrates in retinoblastoma.
- Treatment of RB-deficient retinoblastoma with Aurora-A kinase inhibitor.
- MiR-146a functions as a potential tumor suppressor in retinoblastoma by negatively regulate neuro-oncological ventral antigen-1.
Chordoma
脊索瘤Led 3 of 105 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (23.8%).
- Open trials led
- 0
- Research papers it led
- 3
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.5%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Osteosarcoma
骨肉瘤Led 35 of 2,257 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (4.3%).
- Open trials led
- 0
- Research papers it led
- 35
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.7%
Over half of these papers are lab or animal studies.
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Case report and literature review: A young man with giant intra-abdominal Ewing sarcoma.
- A Hypoxia Gene-Based Signature to Predict the Survival and Affect the Tumor Immune Microenvironment of Osteosarcoma in Children.
- Single-cell and spatial transcriptomics reveal post-translational modifications in osteosarcoma progression and tumor microenvironment.
- ESPN activates ZEB1-mediated EMT through the PI3K/AKT/mTOR axis to promote osteosarcoma metastasis.
- TCF19/CDKN2A Regulates Glycolysis and Macrophage M2 Polarization for Osteosarcoma Progression.
Gastrointestinal stromal tumour
胃肠道间质瘤Led 20 of 523 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (6.3%).
- Open trials led
- 1
- Research papers it led
- 20
- Trials it led
- 2
- Share of China's trials
- 2.7%
- Share of the world's papers
- 1.2%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Laparoscopic versus open resection for unfavorable sites gastric gastrointestinal stromal tumors: a propensity weighted cohort study.
- Using body composition to predict treatment-related adverse events and disease-free survival in patients with gastrointestinal stromal tumors treated with imatinib: a retrospective cohort study.
- Interpretable machine learning model based on CT semantic features and radiomics features to preoperatively predict Ki-67 expression in gastrointestinal stromal tumors.
- Population-based long-term prognosis analysis of subcutaneous gastrointestinal stromal tumors.
- Ligation-assisted endoscopic full-thickness resection combined with preloaded sutures for tiny mesenchymal tumors of the gastric fundus.
Trials on ClinicalTrials.gov3
Neuroblastoma
神经母细胞瘤Led 30 of 1,132 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (8.8%).
- Open trials led
- 3
- Research papers it led
- 30
- Trials it led
- 3
- Share of China's trials
- 7.1%
- Share of the world's papers
- 0.7%
Over half of these papers are lab or animal studies.
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Differentiating Benign from Malignant Renal Tumors Using T2- and Diffusion-Weighted Images: A Comparison of Deep Learning and Radiomics Models Versus Assessment from Radiologists.
- RAS gene polymorphisms confer the risk of neuroblastoma in Chinese children from Jiangsu province.
- Cellular morphometric biomarkers and large language model predict prognosis and treatment response in neuroblastoma patients: A retrospective and double-blind prospective single arm clinical study.
- HOTTIP rs1859168 C > A polymorphism reduces neuroblastoma susceptibility in Chinese children.
- Clinical features and treatment options for pediatric adrenal incidentalomas: a retrospective single center study.
Trials on ClinicalTrials.gov4
- Clinical Application of Somatostatin Receptor and Norepinephrine Transporter Targeted Imaging for Diagnosis and Staging of Neuroblastoma and Pheochromocytoma/Paraganglioma
- Chimeric Natural Killer Receptor-Universal T Cells for Relapsed or Refractory Neuroblastoma
- Clinical Application Study of [123I]Metaiodobenzylguanidine and Somatostatin Receptor-Targeted Imaging in the Diagnosis and Staging of Neuroblastoma
- Study Evaluating the Efficacy and Safety With CAR-T for Relapsed or Refractory Neuroblastoma in Children
Ewing sarcoma
尤文肉瘤Led 2 of 163 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (8.6%).
- Open trials led
- 0
- Research papers it led
- 2
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.2%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Multiple myeloma
多发性骨髓瘤Led 39 of 1,676 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (4.8%).
- Open trials led
- 6
- Research papers it led
- 39
- Trials it led
- 9
- Share of China's trials
- 1.8%
- Share of the world's papers
- 0.4%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Phase 1 study of C-CAR088, a novel humanized anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma.
- Impact of CD34+ cell infusion dose on immune reconstitution and survival in multiple myeloma after autologous stem cell transplantation.
- A Nomogram for Predicting Progression-Free Survival in Primary Extramedullary Multiple Myeloma Using Routine Laboratory Variables.
- The prognostic value of POD24 for multiple myeloma: a comprehensive analysis based on traditional statistics and machine learning.
- Progression of disease within 24 months (POD24) in multiple myeloma implicates poor prognosis and limitations of current prediction models for POD24.
Trials on ClinicalTrials.gov6
- Safety and Efficacy of RN9101 in the Treatment of Relapsed/Refractory Multiple Myeloma
- RN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies
- A Clinical Study to Evaluate LVIVO-TaVec200 for the Treatment of Relapsed/Refractory Multiple Myeloma
- Aspirin vs. Rivaroxaban for Thromboprophylaxis in Multiple Myeloma
- A Prospective Study Comparing DRd With VRd-lite in Elderly Newly Diagnosed Multiple Myeloma
- LCAR-M61S and LCAR-M61D in Treatment of Relapsed/Refractory Multiple Myeloma
B-cell acute lymphoblastic leukaemia (B-ALL)
B 细胞急性淋巴细胞白血病Led 3 of 225 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (8.9%).
- Open trials led
- 1
- Research papers it led
- 3
- Trials it led
- 1
- Share of China's trials
- 0.4%
- Share of the world's papers
- 0.3%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led3
- Identification of a novel MEF2C::SS18L1 fusion in childhood acute B-lymphoblastic leukemia.
- Cell adhesion molecule ITGB2 promotes CAR-T cell therapy in B-cell malignancies.
- Construction of three-gene-based prognostic signature and analysis of immune cells infiltration in children and young adults with B-acute lymphoblastic leukemia.
Trials on ClinicalTrials.gov6
- RN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies
- Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol
- Newly-diagnosed Pediatric Ph-positive B-ALL Protocol
- Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol
- A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)
- A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents
Aplastic anaemia
再生障碍性贫血Led 11 of 412 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (17.2%).
- Open trials led
- 0
- Research papers it led
- 11
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.7%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Comparison of Haploidentical-Hematopoietic Stem Cell Transplantation Using Modified Post-Transplantation Cyclophosphamide and Eltrombopag Combined With Immunosuppression for the Treatment of Severe Aplastic Anemia.
- Combining immunosuppressive therapy with low dosage eltrombopag in Chinese patients with severe aplastic anemia: mild aggravation of hepatic injury.
- Avatrombopag as alternative therapy for severe aplastic anemia patients who are intolerant or unresponsive to eltrombopag.
- Transfusion-dependent non-severe aplastic anemia: characteristics and outcomes in the clinic.
- Comparison of haploidentical-allogeneic hematopoietic stem cell transplantation and intensive immunosuppressive therapy for patients with severe aplastic anemia with an absolute neutrophil count of zero: a retrospective
Haemophagocytic lymphohistiocytosis (HLH)
噬血细胞性淋巴组织细胞增生症Led 25 of 399 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (22.3%).
- Open trials led
- 0
- Research papers it led
- 25
- Trials it led
- 1
- Share of China's trials
- 2.1%
- Share of the world's papers
- 1.6%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Epidemiological, clinical characteristics and prognostic factors analysis of adult patients with hemophagocytic lymphohistiocytosis in a Chinese hospital.
- Perforin Expression and Natural Killer-Cell Proportion as Biomarkers in Secondary Hemophagocytic Lymphohistiocytosis.
- Nomogram for predicting the 30- and 90-day prognoses of hemophagocytic lymphohistiocytosis patients: a multicenter and retrospective study.
- Predicting six-month mortality in adult hemophagocytic lymphohistiocytosis with machine learning: a prognostic approach utilizing laboratory data.
- Elevated fibrosis‑4 index is associated with 30-day mortality in adult hemophagocytic lymphohistiocytosis patients.
Trials on ClinicalTrials.gov2
- Trial of DA-EPOCH Regimen for NHL With HLH
- A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic Characteristics, and Immunogenicity of Plonmarlimab in Subjects With Rheumatic and Immunological Disease-associated Haemophagocytic Lymphohistiocytosis (HLH) (Also Known as Macrophage Activation Syndrome (MAS))
Beta thalassaemia
β 地中海贫血Led 2 of 312 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (9.9%).
- Open trials led
- 0
- Research papers it led
- 2
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.1%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Haemophilia A
血友病 ALed 2 of 272 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (15.8%).
- Open trials led
- 0
- Research papers it led
- 2
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.07%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led2
Trials on ClinicalTrials.gov3
- Study of Efficacy and Safety of FRSW107 in Pediatric Patients With Severe Hemophilia A
- Recombinant Single-chain Factor VIII (rVIII-SingleChain) in Chinese Participants With Hemophilia A Previously Treated With FVIII Products
- Retrospective Chart Review to Evaluate Safety and Tolerability of ADVATE Among Previously Untreated Patients in China With Moderate to Severe Hemophilia A
Neuromyelitis optica spectrum disorder (NMOSD)
视神经脊髓炎谱系疾病Led 4 of 485 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (10.5%).
- Open trials led
- 0
- Research papers it led
- 4
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.2%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led4
- Clinical value of plasma C1q, C3, and C4 in NMOSD and MOGAD.
- Successful treatment with efgartigimod as an add-on therapy in acute attack of anti-AQP4 antibody-positive NMOSD: a case report.
- Plasma Complement 3 and Complement 4 Are Promising Biomarkers for Distinguishing NMOSD From MOGAD and Are Associated With the Blood-Brain-Barrier Disruption in NMOSD.
- Clinical significance of anti-SSA/Ro antibody in Neuromyelitis optica spectrum disorders.
IgG4-related disease
IgG4相关性疾病Led 3 of 246 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (19.1%).
- Open trials led
- 1
- Research papers it led
- 3
- Trials it led
- 1
- Share of China's trials
- 2.3%
- Share of the world's papers
- 0.2%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led3
- SAPHO syndrome complicated by IgG4-related ophthalmic disease: a case report and literature review.
- Coronary Arteritis in Immunoglobulin G4-related Disease.
- The Role of Symptom Duration and Serologic Factors in the Relapse of IgG4-Related Ophthalmic Disease following Surgery: A Retrospective Cohort Study.
Trials on ClinicalTrials.gov1
Myasthenia gravis
重症肌无力Led 5 of 499 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (6.6%).
- Open trials led
- 1
- Research papers it led
- 5
- Trials it led
- 1
- Share of China's trials
- 1.1%
- Share of the world's papers
- 0.2%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Rechallenge of immune checkpoint inhibitors in a case with adverse events inducing myasthenia gravis.
- Efgartigimod for generalized myasthenia gravis in the extreme elderly (≥80 years): a multicenter retrospective real-world study.
- Efgartigimod as a fast-acting add-on therapy in manifest and impending myasthenic crisis: A single-center case series.
- Pneumonia and systemic inflammatory response syndrome as predictors for difficult-/prolonged-weaning after invasive ventilation in myasthenic crisis: A retrospective analysis of a Chinese cohort.
- More evidence is needed for the association between serum myasthenia gravis and adverse pregnancy, delivery, and neonatal outcomes.
Moyamoya disease
烟雾病Led 7 of 356 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (19.9%).
- Open trials led
- 3
- Research papers it led
- 7
- Trials it led
- 3
- Share of China's trials
- 9.1%
- Share of the world's papers
- 0.6%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Integrative molecular subtyping and diagnostic model construction for Moyamoya disease based on diverse programmed cell death gene patterns.
- Single-cell sequencing analysis of peripheral blood in patients with moyamoya disease.
- Construction of Diagnosis Model of Moyamoya Disease Based on Convolution Neural Network Algorithm.
- Baseline Hemodynamic Impairment and Revascularization Outcome in Newly Diagnosed Adult Moyamoya Disease Determined by Pseudocontinuous Arterial Spin Labeling.
- High-resolution compressed sensing time-of-flight MR angiography outperforms CT angiography for evaluating patients with Moyamoya disease after surgical revascularization.
Trials on ClinicalTrials.gov3
- Clinical Safety and Efficacy Evaluation of the Blood-cooling and Stasis-removing Formula as an Adjunct to Atorvastatin in the Treatment of Hemorrhagic Moyamoya Disease.
- Fufang Tongluo Decoction as an Adjunct to Aspirin and Atorvastatin for Ischemic Moyamoya Disease
- Clinical Evaluation of the Safety and Efficacy of "Buyan Huan Wu Tang" Combined With Atorvastatin in the Treatment of Atypical Pneumonia
Wilson disease
肝豆状核变性(Wilson 病)Led 3 of 201 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (7.5%).
- Open trials led
- 0
- Research papers it led
- 3
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.4%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led3
- Unprecedented coexistence of Dent's disease type 1 and Wilson's disease in a two-year-old Chinese boy: implications for precision medicine.
- Discovery of newborn Wilson disease biomarkers via integrated next-generation sequencing and untargeted metabolomics.
- Assessment of sleep disturbance in patients with Wilson's disease.
Biliary atresia
胆道闭锁Led 9 of 214 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (9.8%).
- Open trials led
- 0
- Research papers it led
- 9
- Trials it led
- 2
- Share of China's trials
- 10.0%
- Share of the world's papers
- 1.2%
Over half of these papers are lab or animal studies.
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Development and validation of a nomogram for predicting the clearance of jaundice in children with biliary Atresia after Kasai portoenterostomy.
- Correlation Analysis Between Preoperative Liver Ultrasound Elastography and Postoperative Jaundice Clearance After Kasai Surgery for Biliary Atresia.
- EP300/YAP1-SERPINE1 Signaling Regulates Ductular Reaction and Liver Fibrosis in Biliary Atresia.
- PRAG1 promotes cholangiocyte epithelial-mesenchymal transition and liver fibrosis in biliary atresia.
- Dysregulated Activation of Hippo-YAP1 Signaling Induces Oxidative Stress and Aberrant Development of Intrahepatic Biliary Cells in Biliary Atresia.
Anti-NMDA receptor encephalitis
抗 NMDA 受体脑炎Led 7 of 264 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (10.2%).
- Open trials led
- 0
- Research papers it led
- 7
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.9%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Efgartigimod-rituximab sequential therapy in Anti-NMDAR encephalitis: real-world evidence for a novel salvage-maintenance strategy.
- The presence of human respiratory syncytial virus in the cerebrospinal fluid of a child with Anti-N-methyl-D-aspartate receptor encephalitis of unknown trigger.
- Severity of Hospitalized Children with Anti-NMDAR Autoimmune Encephalitis.
- Association between clinical factors and orofacial dyskinesias in anti-N-methyl-D-aspartate receptor encephalitis.
- Using EEG and MEG to characterize extreme delta brush in a patient with anti-NMDA receptor encephalitis.
Takayasu arteritis
大动脉炎Led 3 of 187 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (24.6%).
- Open trials led
- 0
- Research papers it led
- 3
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.4%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led3
- An alternative catheter to invasive blood pressure monitoring in a patient with Takayasu arteritis undergoing open adrenalectomy: A case report.
- Myocardial dissection caused by Takayasu's arteritis complicated with sinus of Valsalva aneurysm.
- Emergent endovascular repair of a huge aortic arch aneurysm with aortopulmonary fistula secondary to Takayasu's arteritis.
Trials on ClinicalTrials.gov1
Hepatic echinococcosis
肝包虫病Led 2 of 152 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (32.2%).
- Open trials led
- 0
- Research papers it led
- 2
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.4%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Idiopathic pulmonary fibrosis
特发性肺纤维化Led 19 of 989 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (4.3%).
- Open trials led
- 0
- Research papers it led
- 19
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.5%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Associations of combined phenotypic ageing and genetic risk with incidence of chronic respiratory diseases in the UK Biobank: a prospective cohort study.
- Nobiletin's role in idiopathic pulmonary fibrosis via the PI3K/AKT/MDM2/p53 signaling pathway.
- Cytokine Expression Profiling in Idiopathic Pulmonary Fibrosis: Insights From Integrative Proteomic Analysis.
- Alternative Polyadenylation Contributes to Fibroblast Senescence in Pulmonary Fibrosis.
- SZ168 alleviates bleomycin-induced pulmonary fibrosis by inhibiting podoplanin-induced platelet activation.
Amyotrophic lateral sclerosis
肌萎缩侧索硬化症Led 7 of 779 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (8.3%).
- Open trials led
- 0
- Research papers it led
- 7
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.1%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Anti-neurofascin 186 antibody in amyotrophic lateral sclerosis: a case report.
- Early cortical alterations and neuropsychological mechanisms in amyotrophic lateral sclerosis.
- Differed brain spontaneous neural activity between limb-onset and bulbar-onset amyotrophic lateral sclerosis patients.
- Genome-wide association analysis reveals potential genetic correlation and causality between circulating inflammatory proteins and amyotrophic lateral sclerosis.
- The presence and clinical significance of autoantibodies in amyotrophic lateral sclerosis: a narrative review.
Fabry disease
法布雷病Led 3 of 73 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (12.3%).
- Open trials led
- 0
- Research papers it led
- 3
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.4%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led3
Duchenne muscular dystrophy
杜氏肌营养不良Led 3 of 213 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (10.8%).
- Open trials led
- 0
- Research papers it led
- 3
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.1%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led3
- Optimized efficient screening for Duchenne muscular dystrophy carriers using proto-oncogene tyrosine-protein kinase receptor Ret.
- Creatine Kinase-MM/Proto-oncogene Tyrosine-Protein Kinase Receptor as a Sensitive Indicator for Duchenne Muscular Dystrophy Carriers.
- Comprehensive analysis of genomic complexity in the 5' end coding region of the DMD gene in patients of exons 1-2 duplications based on long-read sequencing.
Behçet disease
白塞病Led 4 of 245 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (22.9%).
- Open trials led
- 0
- Research papers it led
- 4
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.3%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led4
- Successful management of oral manifestations of Behcet's disease and Sjogren's disease using washed microbiota transplantation: a case report.
- Multiple aseptic abscesses and pulmonary involvement in a child with Behcet's disease phenotype: a case report.
- Allogeneic hematopoietic stem cell transplantation for juvenile myelomonocytic leukemia with intestinal Behçet's disease: A case report.
- Analysis of the potential relationship between COVID-19 and Behcet's disease using transcriptome data.
IgA nephropathy
IgA 肾病Led 8 of 736 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (9.4%).
- Open trials led
- 0
- Research papers it led
- 8
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.5%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Targeted release of budesonide in primary IgA nephropathy.
- Clinicopathological features and renal outcomes in patients with IgA nephropathy secondary to psoriasis.
- Delta corticomedullary apparent diffusion coefficient on MRI as a biomarker for prognosis in IgA nephropathy.
- A rare case of late-onset immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome confused with IgA vasculitis nephropathy.
- External Validation of the International Prognosis Prediction Model of IgA Nephropathy.
Trials on ClinicalTrials.gov6
- RD06-05 Universal CD19/BCMA CAR-T for Refractory Pediatric Autoimmune Diseases
- A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression
- A Study of Telitacicept for IgA Nephropathy (TELIGAN)
- TESTING -ON Post-Trial ObservatioNal Cohort Study
- Atrasentan in Patients With IgA Nephropathy
- Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy
Primary biliary cholangitis
原发性胆汁性胆管炎Led 2 of 300 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (12.0%).
- Open trials led
- 0
- Research papers it led
- 2
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.2%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led2
Primary sclerosing cholangitis
原发性硬化性胆管炎Led 2 of 100 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (7.0%).
- Open trials led
- 0
- Research papers it led
- 2
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.2%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Hirschsprung disease
先天性巨结肠Led 9 of 161 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (13.0%).
- Open trials led
- 0
- Research papers it led
- 9
- Trials it led
- 2
- Share of China's trials
- 16.7%
- Share of the world's papers
- 1.2%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Comparative efficacy of Soave versus Swenson procedures for Hirschsprung disease: a systematic review and meta-analysis.
- Features of defecation dysfunction among patients with Hirschsprung disease in early childhood.
- For short-segment Hirschsprung disease, daily trans-anal irrigation before pull-through surgery is necessary?
- Bowel function at preschool and early childhood age in children with long-segment Hirschsprung disease.
- m6A demethylase ALKBH5 suppresses proliferation and migration of enteric neural crest cells by regulating TAGLN in Hirschsprung's disease.
Familial adenomatous polyposis
家族性腺瘤性息肉病Led 3 of 59 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (10.2%).
- Open trials led
- 0
- Research papers it led
- 3
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.4%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led3
- Family adenomatous polyposis come across dome type adenocarcinoma: a case report and literature review.
- Comments on "Endoscopic papillectomy for ampullary lesions in patients with familial adenomatous polyposis compared with sporadic lesions: a propensity score-matched cohort".
- Human amnion-derived mesenchymal stem cells promote osteogenic differentiation of lipopolysaccharide-induced human bone marrow mesenchymal stem cells via ANRIL/miR-125a/APC axis.